Compare MLAB & IRWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MLAB | IRWD |
|---|---|---|
| Founded | 1982 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 719.9M | 713.8M |
| IPO Year | 1995 | 2009 |
| Metric | MLAB | IRWD |
|---|---|---|
| Price | $134.63 | $4.58 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 3 |
| Target Price | ★ $94.00 | $7.67 |
| AVG Volume (30 Days) | 105.7K | ★ 1.5M |
| Earning Date | 05-27-2026 | 05-11-2026 |
| Dividend Yield | ★ 0.67% | N/A |
| EPS Growth | 436.11 | ★ 1400.00 |
| EPS | 0.49 | ★ 0.55 |
| Revenue | N/A | ★ $298,276,000.00 |
| Revenue This Year | $6.07 | $57.95 |
| Revenue Next Year | $5.41 | $4.39 |
| P/E Ratio | $269.12 | ★ $8.02 |
| Revenue Growth | N/A | ★ 8.88 |
| 52 Week Low | $63.48 | $1.26 |
| 52 Week High | $132.70 | $5.78 |
| Indicator | MLAB | IRWD |
|---|---|---|
| Relative Strength Index (RSI) | 69.25 | 58.34 |
| Support Level | $94.20 | $3.89 |
| Resistance Level | N/A | $4.52 |
| Average True Range (ATR) | 4.28 | 0.18 |
| MACD | -0.06 | 0.02 |
| Stochastic Oscillator | 100.00 | 77.10 |
Mesa Laboratories Inc manufactures life sciences tools and critical quality control solutions. It operates in four divisions: i) Sterilization and Disinfection Control, which manufactures and sells biological, chemical, and cleaning indicators used to assess the effectiveness of sterilization, decontamination, disinfection, and cleaning processes. ii) Clinical Genomics division develops, manufactures, and sells sensitive, low-cost, high-throughput genetic analysis tools and related consumables. iii) The Biopharmaceutical Development division develops, manufactures, and sells automated systems for protein analysis (immunoassays) and peptide synthesis solutions. iv) The Calibration Solutions division develops, manufactures, sells, and services quality control products.
Ironwood Pharmaceuticals Inc is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal, or GI, and rare diseases. It is focused on the development and commercialization of inventive product opportunities in areas of unmet need, leveraging its demonstrated expertise and capabilities in GI and rare diseases. LINZESS is its commercial product. LINZESS is also available for the treatment of adults with IBS-C or CIC in Mexico, adults with IBS-C or chronic constipation in Japan, and adults with IBS-C in China. Linaclotide is available under the trademarked name CONSTELLA for the treatment of adults with IBS-C or CIC and pediatric patients ages 6-17 years old with FC in Canada, and to adults with IBS-C in certain European countries.